The neuropeptide orexin is synthesized by neurons exclusively located in the hypothalamus. However, these neurons send axons over virtually the entire brain and spinal cord and therefore constitute a unique central orexinergic system. it is well known that central orexin plays a crucial role in the regulation of various basic non-somatic and somatic physiological functions, including feeding, energy homeostasis, the sleep/wake cycle, reward, addiction, and neuroendocrine, as well as motor control. Moreover, the absence of orexin results in narcolepsy-cataplexy, a simultaneous somatic and non-somatic dysfunction. in this review, we summarize these central functions of the orexinergic system and associated diseases, and suggest that this system may hold a key position in somatic-non-somatic integration.
Introduction
in 1998, a novel family of neuropeptides, named orexins or hypocretins, was isolated from the central nervous system by two groups [1, 2] . Using subtraction hybridization, de Lecea et al. [1] first identified the mRNA sequence encoding preprohypocretin, the putative precursor of hypocretins (named for their exclusive expression within the hypothalamus and sharing substantial amino-acid identity with the gut hormone secretin). Almost simultaneously, while searching for endogenous peptide ligands for multiple orphan G proteincoupled receptors, Sakurai et al. [2] identified the same neuropeptides. in view of their stimulation of food intake by central administration, Sakurai et al. [2] called these peptides "orexins", derived from the Greek word "orexis" meaning appetite. it soon became clear that the peptides isolated by the two groups were, in principle, identical. in this review, we use the orexin nomenclature.
orexin is synthesized by neurons located exclusively in the hypothalamus (prefornical area, lateral hypothalamic area (LHA) and posterior hypothalamus) [1] [2] [3] . From this restricted region, the orexinergic neurons project extensively to almost the whole brain, constituting the central orexinergic system [3] [4] [5] . Moreover, orexin and orexin receptors are also found outside the central nervous system, such as in the pancreas and gastrointestinal tract, where they affect insulin release, intestinal motility and secretion [6] . intriguingly, accumulating evidence reveals that the central orexinergic system holds a key position in many important basic physiological functions, including non-somatic regulation, such as feeding, energy homeostasis, the sleep/wake cycle and neuroendocrine, as well as somatic motor control.
Clearly, an intact behavior comprises both somatic (motor) and non-somatic (e.g., visceral, emotional, and cognitive) components and requires somatic-non-somatic integration involving various brain regions and discrete neuronal pathways [7, 8] . By linking the non-somatic centers to somatic motor structures, the central orexinergic system may actively participate in somatic-non-somatic integration, which is crucial for the generation and execution of appropriate and coordinated behavioral responses to changes in the internal and external environments. 
Orexins and Orexin Receptors
There are two splice variants of orexin, A and B (Fig. 1 amino-acid identity. Strong homology is found in their Cterminal halves (73%). The amino-acid sequences of orexins A and B in both non-mammalian vertebrates and mammalian species are conserved [9, 10] , indicating that they are phylogenetically old neurotransmitters/neuromodulators.
Two orexin receptors subtypes, orexin 1 receptor (OX1R) and orexin 2 receptor (OX2R), have been identified (Fig. 1 ). Both belong to the family of G protein-coupled receptors [2] , and they share an overall 64% sequence identity.
OX1R has an order-of-magnitude greater affinity for orexin A than for orexin B, whereas OX2R is relatively nonselective between the two peptides [2, 11] . it is also known that both receptor genes are highly conserved among mammalian species [9, 10] . While orexins are produced in restricted locations of the hypothalamus, orexin receptors are expressed in diverse regions in the brain and spinal cord. Moreover, the distributions of the receptors are generally in agreement with the innervation by orexinergic neurons [12] [13] [14] .
The distribution patterns of OX1Rs and OX2Rs overlap but are partially distinct in the central nervous system.
For instance, regions such as the locus coeruleus, the latero dorsal tegmental nucleus, and the pedunculopontine tegmental nucleus mainly express OX1R, whereas the tuberomammillary nucleus (TMN) of the hypothalamus, the nucleus accumbens, and the septal nuclei mainly express OX2R [15] . The different distribution patterns suggest that the two orexin receptor subtypes play different physiological roles.
it is worthwhile to note that orexinergic neurons typically have varicose axon terminals rather than classical chemical synaptic specializations [16] , and orexin receptors are metabotropic and the orexinergic projections are extensively distributed [9, 10] . Thus, the central orexinergic system may act as a general modulator for whole-brain activity.
Signal Transduction Pathways Coupled to Orexin
Receptors orexins exert a quite uniform excitatory effect on neurons in the central nervous system, although they can also inhibit neurons through undefined presynaptic mechanisms. Fig. 1 ) [11, 17] . on the other hand, besides the G q pathway, OX2Rs may also be independently coupled to other signal transduction pathways. In OX2R-transfected neuron-like cells, orexin inhibits forskolin-stimulated cAMP accumulation in a dose-dependent manner, and this is abolished by pretreatment with pertussis toxin, while in OX1R-transfected cells the inhibitory effect of orexin does not occur [18] , suggesting that OX2Rs are also coupled to the pertussis toxin-sensitive G i/o pathway ( Fig. 1 ) [6] . in addition, interactions between orexin receptors and NMDA channels have been reported [19, 20] .
Central Physiological Functions of Orexin and Related Diseases

Sleep/Wakefulness and Narcolepsy
The central function of orexin that attracts most attention is regulation of the sleep/wake cycle, since orexin-or OX2R-deficient mice and dogs exhibit symptoms strikingly similar to human narcolepsy [21] [22] [23] [24] , that affects ~1/2 000 persons.
Narcolepsy is a chronic sleep disorder characterized by a primary disorganization of behavioral states. A cardinal symptom of narcolepsy is excessive daytime sleepiness, with irresistible sleep attacks at inappropriate times, such as while at work. in narcolepsy patients, the latency for rapid eye-movement (REM) sleep is notably reduced and REM sleep can even intrude directly into wakefulness. it has been reported that human narcoleptics have an 85-95% reduction in the number of orexin neurons [25, 26] . Similarly, orexins are undetectable in the cerebrospinal fluid of these patients [27] .
Experimental studies have provided substantial evidence for the regulation of sleep and wakefulness by the central orexinergic system. orexin A or orexin B, intracerebroventricularly administered at the onset of the normal sleep period, produces a significant increase in the time the animal spends awake and a significant decrease in the proportion of REM and non-REM sleep [28, 29] . Moreover, c-fos expression in orexin neurons [30] and the orexin levels in cerebrospinal fluid [31] correlate positively with the amount of wakefulness and negatively with the amounts of non-REM and REM sleep. Furthermore, in unanesthetized rats, orexin neurons discharge during active waking, reduce discharges during quiet waking, and virtually cease firing during sleep [32] . All of these findings show that orexin neurons are relatively active during wakefulness and inactive during sleep.
Currently, it is agreed that orexin regulates the sleep/ wake cycle through its activation of arousal-promoting monoaminergic systems. orexin receptors are distributed abundantly in monoaminergic neurons in the raphe nuclei, locus coeruleus and TMN [12] [13] [14] . Besides, the regions where monoamine neurons are concentrated receive a large number of projections from orexin neurons [4, 5] . These results suggest that the monoaminergic systems are important targets of orexin neurons. Actually, electrophysiological studies have demonstrated that orexin excites monoamine systems, including noradrenergic neurons in the locus coeruleus [28] , dopaminergic neurons in the ventral tegmental area (VTA) [33] and serotoninergic neurons in the dorsal raphe nuclei [34, 35] as well as histaminergic neurons in the TMN [36] . These monoaminergic neurons project diffusely to the cerebral cortex, thalamus and brainstem, and are highly active during wakefulness, less active during non-REM sleep and rarely active during REM sleep. Thus, it is likely that orexin neurons enhance and stabilize the activity of monoaminergic neurons to promote wakefulness [37] . Be- sides, orexin has a strong and direct excitatory effect on the cholinergic neurons of the basal forebrain which contribute to the cortical activation associated with wakefulness [38] .
Among the monoaminergic systems, the histaminergic neurons in the TMN seem to be the most important target for the orexinergic system in sleep/wake regulation. Several reports demonstrate that orexin promotes arousal mainly by activating histaminergic neurons via OX2Rs [36, 39] . intracerebroventricular infusion of orexin A significantly increases the duration of the waking state. Pretreatment with pyrilamine, a histamine H 1 receptor antagonist, strikingly decreases the orexin A-induced wake time [36] . Similarly, orexin has no effect on the wake time in H 1 -receptor knockout mice when administered centrally [40] . Interestingly, OX1Rs and OX2Rs may play different roles in the regulation of wakefulness.
OX2R knockout mice display clear characteristics of narcolepsy, whereas OX1R knockout mice do not have overt behavioral abnormalities, with only increased fragmentation of sleep/wake states [41] . However, OX1Rs also play an important role in sleep/wake regulation. The narcolepsy syndrome that orexin knockout mice exhibit appears to be much more severe than that of OX2R knockout mice [24] .
Considering that histaminergic TMN neurons express mainly OX2Rs but locus coeruleus norepinephrine neurons express mainly OX1Rs [15] , the histaminergic system originating from the TMN may be a key target for the central orexinergic system to regulate the sleep/wake cycle.
Besides the innervation of wake-promoting monoaminergic neurons, orexin neurons also receive inhibitory GABAergic projections from sleep-active neurons in the ventrolateral preoptic area (VLPo) [42] , which plays a critical role in the initiation of non-REM sleep and the maintenance of both non-REM and REM sleep. Selective deletion of GABA B receptors in orexin neurons results in highly unstable sleep/wake architecture in mice [43] , indicating that 
Motor Control and Cataplexy
Among narcoleptic patients, ~70% experience a dangerous complication named cataplexy. Cataplexy is an attack characterized by the sudden loss of muscle tone, which is most often triggered by strong emotional stimuli. During cataplexy, patients remain conscious. Notably, orexin deficiency in humans, dogs, and rodents results in not only narcolepsy but also cataplexy [9, 21] , highlighting the possibility of a direct modulatory role of orexin in motor control. Since cataplexy is closely associated with narcolepsy and often triggered by strong emotions, the effect of orexin on the motor system has always been considered secondary to its actions on the neuronal circuits controlling sleep or emotions [9, 10] .
However, numerous neuroanatomical and immunohistochemical studies reveal that essential subcortical motor structures, such as the basal ganglia, cerebellum, and vestibular nucleus, receive direct innervation from orexin neurons [4, 5] . Moreover, during movements, orexinergic neurons are particularly active [30, 44] and orexin release increases [45] .
The evidence suggests that the orexinergic system directly participates in central motor control.
orexin neurons in the LHA and prefornical area are known to project to regions in the midbrain, including the substantia nigra (SN) and mesopontine tegmentum [4, 5] . The latter contains the mesencephalic locomotor region and pedunculopontine nucleus, both of which are involved in the initiation and modulation of locomotion and other stereotyped movements. in decerebrate cats, injecting orexin A into the mesencephalic locomotor region reduces the intensity of electrical stimulation required to induce locomotion on a treadmill or even elicits locomotor movements without electrical stimulation [46] . on the other hand, microinjection of orexin A into the pedunculopontine nucleus increases the stimulus intensity required to induce muscle atonia [46] .
Furthermore, orexins dose-dependently and selectively activate GABAergic neurons of the SN pars reticulata and not dopaminergic neurons in the SN pars compacta [47] . injecting orexin A into the pars reticulata reduces the inhibitory effect of the pedunculopontine nucleus on muscle atonia [46] .
in addition, accumbens shell-induced locomotor activity is greatly strengthened by activation of OX2Rs after local orexin A infusion [48] .
Since cataplexy is a sudden and transient episode of loss of muscle tone, the central motor areas/nuclei which directly control muscle tone are particularly focused on. A recent study from our laboratory [49] first reported a direct excitatory effect of orexins on neurons in the cerebellar interpositus nucleus, one of the final outputs of the spinocerebellum, which mainly regulates muscle tone and finetunes ongoing movements of the body and limbs. Furthermore, we demonstrated that orexin increases not only the excitability but also the sensitivity of projection neurons in the lateral vestibular nucleus, which directly contributes to the adjustment of muscle tone for both postural maintenance and alternation between extensor and flexor phases during locomotion [50] . The homogeneous excitatory effect of orexin on these neurons involved in motor control suggests that the central orexinergic system acts to excite motor structures uniformly and in parallel. Therefore, common excitation by orexin may help the motor structures maintain excitability at a certain level and also provide for an appropriate level of sensitivity to inputs coding changes in the internal and external environments. intriguingly, local microinjection of orexin A improves vestibular-related motor behaviors in rats, including posture, balance, and negative geotaxis against the gravitational field [50] , implicating orexin and the central orexinergic system in the direct control of somatic motor behavior. More importantly, the direct motor effect of endogenous orexin is critical when an animal faces a major motor challenge as opposed to during rest and general movements [50] . Thus, during a significant behavioral challenge, the increased excitatory drive and sensitivity due to the release of orexin may be essential for ensuring the prompt and appropriate magnitude of motor responses.
This may account for why, when encountering an unexpected challenge that requires a strong motor response, orexin deficiency results in cataplexy.
Feeding and Energy Homeostasis
in the earlier publications dealing with orexin, it was reported that intracerebroventricular administration promotes feeding [2] . But the orexin-induced food intake is only an acute effect. Chronic continuous intracerebroventricular infusion of orexin A results in an increase in daytime food intake but a decrease in nighttime food intake in rats [51] .
Thus, on the whole, there is almost no increase in the total amount of food intake per day. Many brain regions/nuclei, including the arcuate nucleus (ARC), prefornical area, LHA, dorsomedial hypothalamic nucleus, paraventricular nucleus (PVN), VTA and nucleus accumbens, are effective sites for the injection of orexin to promote feeding [52] . The promotion effect is blocked significantly by central pretreatment with anti-orexin A antibodies and the highly selective OX1R antagonist SB-334867 [53, 54] .
Orexin fibers project densely into the ARC [4, 5] , which an NPY-Y1 receptor-specific antagonist, partially inhibits orexin-induced feeding behavior, suggesting that the NPY system may be one of the downstream pathways by which orexin A stimulates feeding [55] . However, since BiBo3304 does not completely abolish the effect of orexin A, other pathways may also be involved in orexin A-induced feeding behavior. Electrophysiological studies have shown a possible involvement of the anorexigenic pro-opiomelanocortin (PoMC) system. Apart from exciting NPY-containing neurons [56, 57] , orexin also inhibits PoMC-containing neurons in ] i levels [58, 59] . intriguingly, the central orexinergic system may regulate feeding behavior through its innervation of the limbic system [60] . infusion of orexin A into the shell of the nucleus accumbens, a limbic forebrain area strongly linked to eating motivation, increases feeding [48] . Moreover, intraaccumbens shell administration of muscimol, the GABA A receptor agonist, induces intense hyperphagia in rats and high c-fos expression in orexin-containing neurons [61] .
These results indicate that orexin may influence food intake by appetitive modulation.
Despite the fact that orexin significantly increases food intake in the daytime, continuous intracerebroventricular administration has no effect on body weight [51] and daily intraparaventricular orexin treatment even induces weight loss [62] in rats. on the other hand, in orexin-or orexin receptorknockout mice, body weight is increased [23, 41, 63] . All these seemingly paradoxical results indicate that orexin may be actively involved in energy metabolism rather than only in food intake. Actually, feeding is not an isolated behavior but is closely associated with wakefulness, activity and even higher brain functions. in wild-type mice, food deprivation triggers a drop in circulating glucose and leptin levels and an elevation in ghrelin signaling, which leads to the acti- vation of orexin neurons to induce a significant increase in vigilance, exploration and locomotor activity [64] . in contrast, orexin neuron-ablated animals fail to exhibit fastinginduced wakefulness as well as locomotor activity [64] . Thus, it is speculated that reduced energy expenditure may be the reason for the increased body weight in orexin-deficient rodents. More recently, Sellayah et al. [65] reported that mice deficient in orexin gain more weight when fed the same high-fat diet as normal mice. The underlying mechanism involves brown-fat hypoactivity, which also leads to dampening of energy expenditure. Therefore, by modulating energy expenditure, orexin plays an integral role in adaptive energy homeostasis and body weight regulation.
Reward
Psychostimulants, such as amphetamine and methylphenidate, have been widely used to treat narcolepsy; however, interestingly, the phenomenon of drug addiction rarely occurs in these patients [66] . Therefore, it is suggested that the orexinergic system may be necessary for the formation of addiction and plays important roles in reward processing.
This hypothesis was later confirmed in animal models.
Subcutaneous morphine-induced place preference and hyperlocomotion are abolished in orexin knock-out mice, demonstrating a crucial link between the central orexinergic system and reward-seeking behavior [67, 68] .
orexin neurons receive projections from the VTA and nucleus accumbens [42] , both of which are widely implicated in the reward system, drug addiction, and motivation. Correspondingly, the VTA also receives massive inputs from orexin neurons in the LHA and prefornical area [4, 5, 69] . These reciprocal connections may constitute a basis for the involvement of the orexinergic system in the regulation of reward circuitry. Electrophysiological data have documented that orexins directly activate dopamine neurons in the VTA [70] . in addition, both intracerebroventricular infusion of orexin A and its administration directly into the VTA lead to dose-related reinstatement of drug-seeking [71, 72] . Pretreatment of alcohol-preferring rats with the OX1R antagonist SB-334867 completely abolishes the olfactory cue-induced reinstatement of alcohol-seeking behavior [73] . Moreover, in vitro application of orexin A potentiates N-methyl-D-aspartate receptor (NMDAR)-mediated neurotransmission in the neural plasticity relevant to addiction, via PLC/PKC-dependent insertion of NMDARs into VTA dopamine neuron synapses [19] . Furthermore, in vivo administration of SB-334867 blocks locomotor sensitization to cocaine and occludes cocaine-induced potentiation of excitatory currents in VTA dopamine neurons [19] . These results provide substantial evidence for a critical role of orexin signaling in the induction of synaptic plasticity associated with addiction, and in the subsequent reward-seeking behaviors.
intriguingly, the orexinergic system may be also involved in the memory link between stimulus and reward [72] .
Harris et al. Chemical activation of LHA orexin neurons reinstates the extinguished drug-seeking behavior. And this reinstatement effect is completely blocked by prior administration of an OX1R antagonist [72] . These results show that the projections from the LHA orexinergic system to the VTA play an important role not only in the formation of an acute desire for reward, but also in the learning and memory of the reward condition.
Neuroendocrine
The release of many hormones is modulated by orexin.
intracerebroventricular administration of orexins markedly increases plasma adrenocorticotropic hormone and corticosterone levels [74] , suggesting that central orexin activates the hypothalamo-pituitary-adrenal axis. Moreover, after intracerebroventricular injection of orexins, c-fos mRNA increases in a dose-related manner in the parvocellular division of the PVN, a large part of which contains corticotropin-releasing hormone neurons [28, 74] . in addition, recently, Lopez et al. [75] found that the mRNA of growth 
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A in growth hormone secretion [76] . in addition, the central orexinergic system may also modulate the hypothalamopituitary-gonad axis. Campbell et al. [77] found that 75-85%
of gonadotropin-releasing hormone (GnRH) neurons receive projections from orexin neurons, and 85% of GnRH neurons express OX1Rs or OX2Rs. In addition, orexin A activates the release of GnRH in hypothalamus explants [78] .
Moreover, in the brains of narcolepsy patients, the level of luteinizing hormone decreases and the release of luteinizing hormone activated by GnRH declines [79] . All of these results suggest that the central orexinergic system is actively involved in neuroendocrine regulation.
Conclusion
Accumulating evidence reveals that the central orexinergic system, originating from restricted hypothalamic regions, regulates various basic physiological processes, including not only non-somatic regulation, such as feeding, energy homeostasis, the sleep/wake cycle, addiction, and neuroendocrine, but also somatic motor control (Fig. 2) . on the other hand, central motor structures project back to the hypothalamus, such as direct cerebellohypothalamic projections [7, 8] and indirect projections from the vestibular nuclei to the hypothalamus [80] , to influence nonsomatic physiological functions. By bridging the non-somatic centers to somatic motor structures and modulating both non-somatic and somatic activity in parallel, the central orexinergic system, together with the circuits from motor structures to non-somatic centers, may actively participate in the orchestration of somatic-non-somatic integration, which is crucial for the generation and execution of appropriate and coordinated behavioral responses (including both somatic and nonsomatic components) to changes in the internal and external environments. Actually, narcolepsy-cataplexy caused by orexin deficiency is a simultaneous somatic and nonsomatic dysfunction in which somatic (motor) activity and some non-somatic (sleep and emotional) responses are not 
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correctly integrated and coordinated. Thus, further studies on the somatic and non-somatic functions of the orexinergic system and the underlying mechanisms will assist not only in understanding and reevaluating the functional roles of orexin, but also in comprehending the entire mechanism of somatic-non-somatic integration, which will help to explain the pathogenesis of simultaneous somatic and non-somatic dysfunctions.
